Hairy Cell Leukemia Variant
3 clinical trials · Condition
◉ Watch Hairy Cell Leukemia Variant
| Record | Firm | Date |
|---|---|---|
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (NCT04815356) | National Cancer Institute (NCI) | 2022-05-23 |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (NCT01841723) | National Cancer Institute (NCI) | 2013-04-30 |
Track Hairy Cell Leukemia Variant automatically
Every clearance here is in the API, with alerts when new ones post.